The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop an easy-to-administer antiviral pill for COVID-19.
The mid-to-late-stage study will test Pfizer’s drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed asymptomatic COVID-19 infection.
In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
To date, Gilead Sciences Inc’s intravenous drug remdesivir is the only approved antiviral treatment for COVID-19 in the United States.
U.S. to donate half a billion additional Pfizer COVID-19 vaccines
Pfizer has also started another study of PF-07321332 in non-hospitalized, symptomatic adult patients.
Merck and partner Ridgeback Biotherapeutics recently launched a late-stage trial of their experimental drug molnupiravir for prevention of the COVID-19 infection.
Molnupiravir is also being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of
hospitalization or death.
(Reporting by Manojna Maddipatla and Amruta Khandekar in Bengaluru; Editing by Krishna Chandra Eluri)
© 2021 Reuters